GCP
MRKR icon

GSA Capital Partners’s Marker Therapeutics MRKR Stock Holding History

GSA Capital Partners’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-14,863
Closed -$216K – 1341
2020
Q4 		$216K Buy
14,863
+6,072
+69% +$94.3K 0.04% 937
2020
Q3 		$132K Buy
8,791
+6,946
+376% +$127K 0.02% 1090
2020
Q2 		$38K Sell
1,845
-9,025
-83% -$197K 0.02% 546
2020
Q1 		$207K Sell
10,870
-5,857
-35% -$149K 0.05% 732
2019
Q4 		$482K Buy
+16,727
New +$609K 0.06% 677

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GSA Capital Partners's MRKR Position: Q1 2021 in Review

GSA Capital Partners sold out of Marker Therapeutics (MRKR) in Q1 2021, closing a stake of 14,863 shares — an estimated $216K sold.

GSA Capital Partners first reported a position in MRKR in Q4 2019 and held it in 5 quarters. The position peaked at $482K in Q4 2019. 74 funds tracked by Wall St. Rank hold MRKR as of Q1 2021.

  • GSA Capital Partners reported no remaining Marker Therapeutics position as of Q1 2021 after selling out during the quarter.
  • GSA Capital Partners sold 14,863 Marker Therapeutics shares in Q1 2021, an estimated $216K.
  • GSA Capital Partners first reported a position in Marker Therapeutics in Q4 2019 and held it in 5 quarters.
  • GSA Capital Partners's Marker Therapeutics position peaked at $482K in Q4 2019.
  • 74 funds tracked by Wall St. Rank held Marker Therapeutics as of Q1 2021.

Based on GSA Capital Partners's 13F filing for Q1 2021, filed 10 May 2021.